Headquarters: Lausanne, Switzerland
Founded: 2016
Ticker: Private
Website: asceneuron.com
Asceneuron is a Swiss biotechnology company focused on developing small molecule therapeutics targeting tau pathology in Alzheimer's disease and other neurodegenerative disorders. The company's lead program, ASN51, is a novel tau aggregation inhibitor that represents a differentiated approach to addressing tau pathology, which correlates strongly with cognitive decline in AD patients[1].
Asceneuron's platform focuses on:
| Attribute | Details |
|---|---|
| Mechanism | Tau aggregation inhibitor |
| Target | Pathological tau species |
| Indication | Alzheimer's disease |
| Stage | Phase 1/2 |
| Trial ID | NCT04759365 |
Clinical Development:
| Program | Target | Indication | Stage |
|---|---|---|---|
| ASN51 | Tau aggregation | Alzheimer's disease | Phase 1/2 |
| Discovery programs | Tau pathology | Neurodegeneration | Discovery |
Tau aggregation inhibitors target the pathological accumulation of tau protein into neurofibrillary tangles (NFTs), which are a hallmark of Alzheimer's disease and several other dementias. Unlike antibody approaches that target extracellular tau, small molecule inhibitors can potentially:
Title: Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Oral ASN51 in Healthy Subjects and Subjects With Alzheimer's Disease
Status: Completed
Enrollment: 25 subjects
Start Date: June 2021
Completion: August 2022
Objectives:
Title: Study of ASN51 in Adults With Early Alzheimer's Disease
Status: Terminated
Enrollment: 123 subjects
Start Date: October 2024
Completion: November 2024
Tau pathology correlates more strongly with cognitive impairment than amyloid plaques, making tau aggregation an attractive therapeutic target:
Asceneuron's tau aggregation inhibitor approach competes with:
Partnerships: Collaborates with academic institutions and pharmaceutical partners
Funding: Raised Series A and B funding from European investors
Location: Based in Lausanne, Switzerland biotech hub